DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: NNC0519-0130

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 114

Registration Number: NCT06718998

Locations: 🇦🇹
Clinical Trials Unit / Center for Medical Research, Graz, Austria

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CagriSema (cagrilintide B and semaglutide I)
Drug: CagriSema A

First Posted Date: 2024-12-04

Last Posted Date: 2025-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT06716307

Locations: 🇺🇸
Celerion, Lincoln, Lincoln, Nebraska, United States

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Conditions: Growth Hormone Deficiency
Neoplasms
Diabetes Mellitus Type 2

Interventions: Drug: Somapacitan

First Posted Date: 2024-11-29

Last Posted Date: 2025-02-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 500

Registration Number: NCT06709040

Locations: 🇬🇧
University of Glasgow, Glasgow, Scotland, United Kingdom

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: NNC0363-1063
Drug: Placebo
Drug: Insulin degludec

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 154

Registration Number: NCT06685185

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease

Conditions: Systemic Inflammation (hsCRP)

First Posted Date: 2024-10-23

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 756

Registration Number: NCT06655493

Locations: 🇸🇦
National Guard Hospital_Riyadh, Riyadh, Saudi Arabia
🇸🇦
Dr. Sulaiman Al Habib Medical Group- Olaya, Riyadh, Saudi Arabia
🇸🇦
King Khaled University Hospital,King Saud Univ. Med. City, Riyadh, Saudi Arabia

and more 19 locations

A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men

Phase 1

Recruiting

Conditions: Haemophilia A

Interventions: Drug: NNC0442-0344 A
Drug: Placebo

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 92

Registration Number: NCT06649630

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

Phase 1

Recruiting

Conditions: Healthy Volunteers Type 2 Diabetes

Interventions: Drug: Semaglutide B
Drug: Semaglutide J
Drug: Semaglutide N
Drug: Semaglutide L
Drug: Semaglutide M

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 90

Registration Number: NCT06642584

Locations: 🇨🇦
Altasciences, Montreal, Quebec, Canada

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: NNC0519-0130 B
Drug: NNC0519-0130 C

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT06642571

Locations: 🇺🇸
ICON, San Antonio, Texas, United States

A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

Phase 1

Recruiting

Conditions: Healthy Volunteers
Heart Failure

Interventions: Drug: NNC0537-1482
Drug: Placebo

First Posted Date: 2024-10-03

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT06625307

Locations: 🇳🇱
ICON - location Groningen, Groningen, Netherlands

A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Phase 3

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Etavopivat
Drug: Placebo

First Posted Date: 2024-09-25

Last Posted Date: 2025-05-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 408

Registration Number: NCT06612268

Locations: 🇫🇷
Ap-Hp-Hopital Henri Mondor, Créteil, France
🇳🇱
UMC Utrecht, Van Creveldkliniek, Utrecht, Netherlands
🇺🇸
Uni of Alabama at Birmingham, Birmingham, Alabama, United States

and more 152 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy